Overwhelming evidence indicates that CSF p‐tau is increased in patients with AD (both in the prodromal and dementia stages) compared to controls (Hansson et al, 2006; Shaw et al, 2009; Mattsson et al, 2009; Olsson et al, 2016). The gene discussed is MAPT; the disease is Alzheimer disease.